Your clinical practice will span the full breadth of modern vascular surgery. This is a true generalist role where you will perform open surgical reconstructions, complex endovascular interventions, and the essential bread-and-butter cases that keep a vascular surgery practice running. The group was built with the explicit understanding that every surgeon must be comfortable across the entire spectrum of vascular care. Dialysis access, chemotherapy port placement, carotid endarterectomy, aneurysm repair, venous interventions, and lower extremity revascularization are all part of the weekly workflow. There is no room here for a narrow subspecialty focus, and that is by design. As the program grows toward four or five surgeons, there will be opportunity to develop areas of focused interest, but today the practice needs surgeons who can handle whatever comes through the door with confidence and independence.
The defining clinical mission of this vascular program is advanced limb salvage. SMG's interventional cardiologists pioneered a CLI program at TMH before the vascular surgeons arrived, and the addition of vascular surgery created the collaborative infrastructure needed to perform the most advanced revascularization procedures available. This is where the embedded cardiology relationship pays its greatest clinical dividend. You will work alongside interventional cardiologists who are deeply committed to CLI and who bring complementary endovascular skills, shared decision-making, and a referral pipeline that feeds both disciplines.
The procedures being performed here are not routine peripheral interventions. The program has brought deep venous arterialization (DVA) via LimFlow to Tallahassee, a procedure performed at relatively few centers nationally. The Detour procedure is performed jointly between interventional cardiology and vascular surgery. Antegrade and retrograde tibial interventions for chronic total occlusions are part of the regular case mix. The ideal candidate for this role is a surgeon who not only performs fem-distal bypasses (fem-tibial, fem-pedal) with confidence but who is genuinely energized by the challenge of saving limbs that other programs would amputate.
In most markets, vascular surgery and interventional cardiology coexist in tension. Turf disputes over peripheral cases, competing referral patterns, and institutional politics create friction that drains energy and limits program growth. This practice was built specifically to eliminate those dynamics. Because both vascular surgery and interventional cardiology are employed under the same group (SMG), you share the same goals, the same patients, and the same financial incentives. There is no competition between disciplines. Cases are discussed openly, opinions are shared freely, and complex procedures are co-managed or co-performed based on what is best for the patient.
The practical benefits are significant. Interventional cardiologists refer carotid disease, aneurysms, and surgical candidates directly to you because you are part of their group and they trust the outcome. You provide surgical backup for catheter-based complications in real time because you are on the same campus and on the same team, not across town with a 30-minute response time. Equipment requests are handled through a single procurement process, and when the interventional team gains access to new technology or trials, vascular surgery benefits from the same institutional relationships.
You will practice in a well-equipped environment with access to the tools required for advanced vascular work. TMH's main campus includes four heart catheterization labs (two designated for peripheral procedures), hybrid-capable operating rooms, and a full complement of advanced imaging. The practice operates with a standing commitment from leadership to provide whatever equipment is needed to support complex revascularization, and current surgeons confirm that commitment has been honored consistently.
A cardiovascular-only Ambulatory Surgery Center (ASC) is opening in spring 2026 in a newly acquired building adjacent to the main campus. The ASC will include two procedural labs, vascular surgery office space, and dedicated infrastructure for outpatient vascular cases. The shell space is built and ready for build-out. This ASC represents a significant expansion of procedural capacity and, for partners, an equity investment opportunity with real estate participation and operational profit sharing. The facility is a joint venture between SMG and TMH, with TMH holding 51% majority ownership. SMG physicians will select the medical director and have direct input on operational design, with an explicit focus on efficiency that avoids the scheduling delays common in the main hospital environment.
The Tallahassee Research Institute (TRI) provides access to industry-sponsored clinical trials, an established IRB, and dedicated research coordinators. Vascular surgery participates in the same research infrastructure that supports SMG's interventional cardiology and EP programs, which have active enrollment in trials including CHAMPION and OPTION. For a surgeon with research interests, this is a meaningful differentiator from typical community practice positions.
TMH's developing affiliation with Florida State University (FSU Health) is expected to create additional academic opportunities over time, including teaching roles within the existing internal medicine residency program and eventual participation in a planned cardiology fellowship. FSU's involvement brings state capital resources, academic infrastructure, and long-term institutional growth that strengthens the program's position as a destination center.
There is one other vascular surgery group in Tallahassee. They are a six-surgeon practice that has operated in the market for decades and recently sold to a private equity firm. Both groups hold privileges and perform procedures at TMH. The competitive dynamic is real, and at times contentious. The other group has pushed back as SMG's vascular program has grown and captured market share.
This is disclosed because the right candidate needs to understand what they are walking into. The SMG vascular team views this competition as a strategic advantage for the right surgeon. You are joining the newer, more innovative, and more forward-aligned program. You are on the inside of the FSU Health transition. You are embedded within the region's dominant cardiology group with a direct referral pipeline. And as the senior partners in the competing group approach retirement, the market dynamics will continue to shift in your favor.
This is a clinical environment where your scope is broad, your volume is real, your colleagues are collaborative, and your ability to practice advanced vascular surgery is limited only by your own ambition and skill. For a surgeon who wants to build something meaningful rather than maintain someone else's status quo, this is the opportunity.